Portfolio

  • InfoBionic receives Frost & Sullivan award for Innovation

    July 27, 2016

    July 27, 2016  Based on its recent analysis of the arrhythmia detection and monitoring market, Frost & Sullivan recognizes InfoBionic with the 2016 North America Frost & Sullivan Award for New Product Innovation. InfoBionic’s MoMe® Kardia system plugs the gaps in traditional cardiac arrhythmia detection devices by optimizing its clinical utility for patients and physicians alike. MoMe Kardia is a wireless remote monitoring system that aids in the detection, management, and diagnosis of cardiac arrhythmias.   Press Release

    Read More
  • Remedy Pharmaceuticals Receives FDA Fast Track Designation

    June 8, 2016

    June 08, 2016 - Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA™ Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug, CIRARA, for the treatment of Large Hemispheric Infarctions (LHI). Press Release

    Read More
  • GI Windows Announces Data from FIH Study

    May 24, 2016

    May 24, 2016 GI Windows, a clinical-stage medical device company, today announced the presentation of six-month results of the first-ever clinical study evaluating the endoscopic creation of a dual-path enteral diversion using the company’s Incision-less Anastomosis System (IAS) at Digestive Disease Week® 2016 (DDW), in San Diego, Calif. The data support the safety and efficacy of GI Windows’ IAS as a treatment option for Type 2 diabetes in obese patients. Press Release

    Read More
  • Remedy Pharmaceuticals Presents at American Academy of Neurology Meeting

    April 12, 2016

    April 12, 2016 - Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that results from its Phase 2 trial of CIRARA™ for preventing edema (brain swelling) in large hemispheric infarctions will be presented during two oral presentations at the 68th annual American Academy of Neurology (

    Read More
  • FineHeart Raises €6.4M Series A led by Broadview Ventures

    March 22, 2016

    March 22, 2016 FineHeart, a Bordeaux-based medical device company focused on creating innovative technologies in the cardiovascular space, has raised 6.41 million euro in a Series A financing. The funds, which have come from a total of six investors led by Broadview Ventures (Boston, MA), will be used to finance the development of FineHeart’s first product. Press Release

    Read More
  • Edwards Lifesciences Corporation Acquires CardiAQ Valve Technologies

    August 26, 2015

    Aug. 26, 2015, Irvine, CA — Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has closed its acquisition of CardiAQ Valve Technologies, Inc., a privately held company and developer of a transcatheter mitral valve replacement system. Edwards announced last month that it had signed an agreement to acquire CardiAQ.   Press Release

    Read More
  • Remedy Pharmaceuticals Publication

    July 28, 2015

    July 28, 2015, New York — Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA, a breakthrough drug treating acute central nervous system conditions such as stroke, today announced publication of a peer-reviewed paper that confirms administering CIRARA for pharmacological targeting of the Sur1-Trpm4 channel in human ischemic stroke to reduce blood-brain barrier disruption and cerebral edema is a promising therapeutic strategy. Press Release

    Read More
  • 480 Biomedical, Inc. Receives $1.2M from Broadview

    June 18, 2015

    June 18, 2015, Watertown, MA — 480 Biomedical, Inc., a clinical stage company developing novel bioresorbable scaffold products for the vasculature, announced today $1.2 million in funding from Broadview Ventures. The financing is a second close on a previously announced $10.5 million in Series C funding round from existing investors. The Broadview funds will support the development of a bioresorbable scaffold to treat children with pulmonary artery stenosis (PAS), a narrowing in the branches of the pulmonary artery that reduces blood flow to the lungs and can lead to heart failure. Press R

    Read More
  • Pulmokine Receives $1M from Broadview

    March 3, 2015

    March 3, 2015 Pulmokine announced today that it has entered into an agreement with Broadview Ventures for $1 Million. Proceeds will be used to advance Pulmokine’s lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH). Press Release

    Read More
  • Aria CV, Inc. Raises $6.3M Series A

    December 19, 2014

    December 19, 2014 Aria CV, Inc., Saint Paul, MN—a developer of medical devices to treat heart failure related to pulmonary hypertension, today announced the initial closing of a $6.3 million Series A preferred equity financing. The financing round was led by Catalyst Health Ventures and includes Broadview Ventures and Cedar Point Capital.  The proceeds from this financing will be used to advance development and perform clinical testing of the device. Press Release

    Read More